Efficacy and safety of SHR-1811-based combination regimens in advanced HER2-overexpressing urothelial carcinoma: a single-center, multi-cohort, Exploratory research

Category Primary study
Registry of TrialsChinese Clinical Trial Register
Year 2026
This article has no abstract
Epistemonikos ID: 4dd5b017b9b805cdaa3e863f0c7d0998805c3f28
First added on: Mar 07, 2026